Genentech (RHHBY) Submits Supplemental Biologics License Application To FDA For Lucentis Indication In Diabetic Retinopathy
8/8/2014 10:34:47 AM
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company has submitted a supplemental Biologics License Application (sBLA) for Lucentis® (ranibizumab injection) to the U.S. Food and Drug Administration (FDA) for the treatment of diabetic retinopathy. The submission is based on results of the RISE and RIDE Phase III clinical trials demonstrating the safety and efficacy of Lucentis for this serious eye disease. There are currently no ocular medications approved for the treatment of diabetic retinopathy.
Help employers find you! Check out all the jobs and post your resume.
comments powered by